Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in innovative companies, includes Intellia as a top 10 holding in one of her firm's actively managed ETFs.

Other actors on Wall Street seem to agree with the pick. The biotech's current price target of $84.22 (according to Yahoo! Finance) represents an upside of about 190% over its current share price of just under $29. Can Intellia Therapeutics live up to this optimism? Let's find out.

Intellia's market capitalization is $2.56 billion. That's despite the fact that the company has no product on the market. And even worse, none of its programs are yet in late-stage clinical trials. It's always hard to value clinical-stage biotech stocks, but at first glance, this market cap seems too high. The market must be valuing the company's candidates highly.

Continue reading

Source Fool.com